Get the Daily Brief

All action, no filler. BioBriefs delivers the industry’s 10 must-know updates, every morning.

Latest Biotech News

Mass‑spec scales multiomics: instruments boost throughput and depth

November 01, 2025

Mass spectrometry vendors pushed new hardware and workflows—such as the Orbitrap Astral Zoom MS—raising throughput to hundreds of samples per day and improving depth to measure ~8,000 proteins per...

Regulatory pivot: FDA signals deregulatory moves as key PDUFAs loom

November 01, 2025

FDA Commissioner signaled forthcoming 'deregulatory' actions following the agency’s relaxation of some biosimilar trial requirements, indicating further shifts imminently. Separately, industry...

Metsera M&A fight erupts: Pfizer sues as Novo tops bid

November 01, 2025

Pfizer moved to block Novo Nordisk’s unsolicited takeover attempt for obesity biotech Metsera after Novo lodged a higher bid, escalating a high‑stakes M&A battle in the obesity drug market. Pfizer...

FDA halts Intellia’s CRISPR trials – liver safety alarm

November 01, 2025

The FDA placed a formal clinical hold on two Phase 3 studies of Intellia Therapeutics’ CRISPR editing candidate nexiguran ziclumeran (nex‑z) after a severe liver adverse event prompted the company...

UCL–UCLA gene therapy posts milestone: durable ADA‑SCID cures reported

November 01, 2025

A collaborative UCL and UCLA gene therapy program reported durable immune reconstitution in children with ADA‑SCID, achieving reported success rates near 95% with no long‑term safety signals in...

Human kidney organoids scaled and grafted into porcine kidneys

November 01, 2025

Researchers developed a scalable, reproducible method to produce thousands of human kidney organoids and demonstrated integration of those organoids into perfused porcine kidneys ex vivo. The...

AI accelerates discovery…models and infrastructure scale up

November 01, 2025

Two developments point to AI’s expanding role in drug discovery: academic and industry groups released Boltz‑2, an AI model that predicts small‑molecule binding affinity at speed, and the Chan...

CAR‑T market jitters: sales slip even as axi‑cel shows clinical promise

November 01, 2025

Commercial dynamics for cell therapies are shifting: Gilead reported an 11% drop in cell‑therapy revenue for the quarter, citing lower demand for Yescarta and Tecartus, while a separate clinical...

Thermo Fisher to buy Clario for $8.88B – clinical data play

November 01, 2025

Thermo Fisher Scientific agreed to acquire Clario Holdings for $8.88 billion in cash to bolster its clinical data and endpoint capabilities. The deal—announced by Thermo Fisher—adds Clario’s...

FDA signals deregulatory push; biomarkers rise in agency agenda

November 01, 2025

FDA leadership signaled further deregulatory initiatives while CDER Director George Tidmarsh outlined agency efforts to reassess surrogate endpoints and expand biomarker use for accelerated...

HHS greenlights 340B rebate pilots — hospitals push back

November 01, 2025

HHS and HRSA approved multiple drugmaker proposals to test a 340B rebate model that shifts discounts to post‑dispense rebates rather than upfront discounts, prompting immediate objections from...

Nanoparticles deliver IL‑12 to tumors — MIT shows striking preclinical efficacy

November 01, 2025

MIT researchers engineered polymer‑coated nanoparticles that concentrate and release interleukin‑12 (IL‑12) within ovarian tumors, dramatically boosting responses to checkpoint inhibitors in mice....

Pfizer sues Novo Nordisk: Court fight erupts over Metsera takeover

November 01, 2025

Pfizer filed litigation in the Delaware Court of Chancery after Novo Nordisk launched a rival bid for Metsera, challenging the validity of Novo’s unsolicited offer and seeking to block Metsera...

FDA halts Intellia’s CRISPR trials: Regulator opens formal review after liver toxicity

November 01, 2025

The U.S. Food and Drug Administration placed formal clinical holds on two Phase 3 trials of Intellia Therapeutics’ CRISPR candidate nexiguran ziclumeran (nex‑z) following a grade‑4 liver adverse...

Scalable kidney organoids...porcine platform bridges supply and transplantation testing

November 01, 2025

Researchers reported a scalable method to produce thousands of uniform human kidney organoids and demonstrated their delivery and short‑term integration into perfused porcine kidneys during ex...

Nanoparticles deliver IL‑12: Local cytokine therapy clears metastatic ovarian tumors in mice

November 01, 2025

MIT and collaborators published preclinical data showing polymer‑coated nanoparticles that deliver IL‑12 into the tumor microenvironment markedly enhanced checkpoint inhibitor activity and...

Myeloid IFNγ signaling tied to ICI resistance in renal cancer

November 01, 2025

Researchers at Dana‑Farber Cancer Institute identified interferon‑gamma (IFNγ) signaling within tumor‑associated myeloid cells as a mechanism driving resistance to immune checkpoint inhibitors...

Gene therapy restores immune function in ADA‑SCID: Multi‑year follow‑up shows high cure rate

November 01, 2025

A joint UCL–UCLA team reported multi‑year follow‑up data in The New England Journal of Medicine showing a gene therapy for ADA‑SCID achieved approximately 95% success restoring immune function...

Google’s AI proposes validated cancer combo: Foundation model finds therapeutic leads

November 01, 2025

Google published results from a foundation model family (Cell2Sentence‑Scale/Gemma) that proposed and helped validate a new cancer drug combination, marking a milestone in AI‑driven biomedical...

From one‑off to pathway: Baby KJ team publishes FDA interactions to scale bespoke gene editing

November 01, 2025

Scientists behind the emergency CRISPR treatment for 'Baby KJ' published the FDA interactions and mapped a regulatory pathway for bespoke gene therapies, offering a template for academic and...